ASCOconnection.org features blogs from ASCO members, the online version of the membership magazine, a discussion area, working groups, and links to the ASCO Membership Directory, Career Center, and Volunteer Portal.
ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe.
ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care.
ASCO eLearning serves as a comprehensive online learning center that supports lifelong learning for physicians, advanced practice providers, and patient educators at every stage of their careers.
A cutting-edge health information technology platform, CancerLinQ™ enables practitioners to learn from individual patients. By assembling vast amounts of usable, searchable, real-world data, CancerLinQ seeks to improve the quality and value of cancer care.
Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for and about them to help patients and families make informed health care decisions.
The Conquer Cancer Foundation funds breakthrough cancer research and shares cutting-edge knowledge with patients and physicians worldwide by improving quality of and access to care and by enhancing quality of life for all who are touched by cancer.
ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant.
The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and ASCO members.
CHICAGO – The randomized OSLO-COMET trial found that laparoscopic surgery did not change chances of survival, when compared to open surgery, to remove metastases that had spread to the liver in patients with colorectal cancer. Overall, patients lived more than 6.5 years after surgery, regardless of whether it was laparoscopic or open.
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria, as proposed by ASCO and Friends of Cancer Research in 2017, would nearly double the percentage of patients eligible to enroll in clinical trials – from 52.3% to 98.5%. The expanded clinical trial eligibility criteria would allow aNSCLC patients with brain metastases, previous or concurrent cancers, and limited kidney function to enroll in clinical trials.
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – A single arm, phase II clinical trial of 125 patients showed treatment with enfortumab vedotin (EV) – a new agent targeting Nectin-4, a protein found in 97% of urothelial cancers – produced responses in 44% of patients with locally advanced or metastatic forms of urothelial cancer. Patients had previously been treated with platinum chemotherapy and a PD-1 or PD-L1 immune checkpoint inhibitor, but the cancer had progressed despite these treatments.
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – A recent survey of U.S.-based physician members of the Society of Gynecologic Oncology found that 64% of respondents experienced sexual harassment in training or practice; among women, the rate was 71% and among men it was 51%. Only 10% reported the incident(s) to officials. In addition, women were more likely than men to respond that gender affected career advancement (34% vs. 10%) and played a role in setting their salary (42% vs. 6%).
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – A new study analyzing demographic statistics from the National Cancer Database identified multiple socio-economic factors, including private insurance, living in a regionally higher-income area, and receiving treatment in certain practice settings as being associated with longer survival for patients with multiple myeloma. Furthermore, researchers found that neither race (black or white) nor gender had a significant impact on survival.
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – Previous racial disparities in timely cancer treatment between African American and white patients practically disappeared in states where Medicaid access was expanded under the Affordable Care Act (ACA), according to a new analysis of electronic health records of over 30,000 patients. The study, based on data from Flatiron Health, also found that after Medicaid expansion African American patients had the greatest rate of improvement in receiving care within 30 days of diagnosis as compared with white patients.
These findings will be presented in ASCO’s Plenary Session, which features four studies of great importance to patient care, out of the 5,600 abstracts accepted to the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – An analysis of data from the National Cancer Database found that after implementation of the 2010 Affordable Care Act (ACA), ovarian cancer was diagnosed and treated at an earlier stage among women under age 65. More women also received treatment within 30 days of diagnosis, thereby increasing chances of survival.
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – An interim analysis of the international randomized, phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer (mHSPC) who received the non-steroidal anti-androgen (NSAA) medicine enzalutamide (Xtandi) along with the standard of care treatment were alive after 3 years compared with 72% of men who received other NSAAs along with standard treatment. The study was led by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.
These findings will be presented in ASCO’s Plenary Session, which features four studies of great importance to patient care, out of the 5,600 abstracts accepted to the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – The randomized, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib (Lynparza) significantly delayed the progression of metastatic pancreatic cancer in patients with BRCA gene mutations compared with placebo (median progression-free survival: 7.4 months vs. 3.8 months, respectively). In the trial, olaparib was administered to patients with cancer that had not progressed after completion of initial platinum-based chemotherapy, and after two years, 22.1% of people receiving olaparib had no disease progression vs. 9.6% for those treated with placebo. While overall survival data are not yet mature, this is a significant advance given that the median survival of metastatic pancreatic cancer is currently less than one year.
These findings will be presented in ASCO’s Plenary Session, which features four studies of great importance to patient care, out of the 5,600 abstracts accepted to the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
CHICAGO – The international, randomized phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone. After 42 months of follow-up, the survival rate was 70% for women who took the combination therapy compared with 46% for women who received endocrine therapy only. Advanced breast cancer is the leading cause of cancer death in women 20 to 59 years of age.
CHICAGO – The KEYNOTE-062 phase III randomized clinical trial achieved its primary endpoint, showing that for patients with PD-L1-positive, HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) cancer, initial therapy with pembrolizumab (Keytruda) resulted in comparable (non-inferior) overall survival as standard chemotherapy. Additionally, pembrolizumab showed clinically meaningful improvement in overall survival among patients with tumors that had high levels of PD-L1 expression. At two years, 39% of patients (all of whom had high PD-L1 levels) that received pembrolizumab alone were alive, compared with 22% of people who received standard chemotherapy. The trial also evaluated combined treatment with pembrolizumab and standard chemotherapy but found this regimen did not improve survival relative to chemotherapy alone.
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
CHICAGO – Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab (Keytruda) was safe and effective and substantially increased overall survival for advanced non-small cell lung cancer (aNSCLC). Specifically, 23.2% of people who had not previously been treated with chemotherapy and 15.5% of previously-treated patients were alive after five years, with the greatest benefit observed in patients with higher PD-L1 expression. This represents a marked improvement over 5-year survival rates from the pre-immunotherapy era, which averaged 5.5% for aNSCLC. This is the longest follow-up study to date of people with aNSCLC treated with pembrolizumab, according to the researchers.
The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and is in press with the Journal of Clinical Oncology.
Chicago — In an effort to advance cancer data sharing and improve the quality and coordination of patient care, three of the nation’s leading health and technology organizations have established a core set of data elements and recommended technical specifications (the Minimal Common Oncology Data Elements, or “mCODE”) that are essential for capturing and reporting the characteristics, treatments, and outcomes of every cancer patient and should be contained in each patient’s electronic health record (EHR). The mCODE™ initiative, a collaboration between the American Society of Clinical Oncology, Inc. (ASCO®), its wholly owned nonprofit subsidiary CancerLinQ LLC, the MITRE Corporation, and the Alliance for Clinical Trials in Oncology Foundation (Alliance Foundation), released the initial set of common cancer data standards and specifications today at ASCO’s 2019 Annual Meeting in Chicago and published them online at mCODEinitiative.org.
The American Society of Clinical Oncology (ASCO) today announced the Health Policy Leadership Development Program Fellows for the 2019-2020 class. Wendy Allen-Rhoades, MD, of Baylor College of Medicine, and Laura LaNiel Tenner, MD, MPH, of The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, will spend the next year developing leadership skills and healthcare policy expertise. During their fellowship, Dr. Allen-Rhoades and Dr. Tenner will participate in ASCO efforts to shape cancer-related policies that directly affect individuals with cancer and the oncology practice environment.
ALEXANDRIA, Va. — Positive findings from fully enrolled cohorts in non-small cell lung cancer and metastatic breast cancer from the American Society of Clinical Oncology, Inc.’s (ASCO) Targeted Agent and Profiling Utilization Registry (TAPUR™) Study will be presented in poster sessions at the 2019 ASCO® Annual Meeting. In addition, the study is being expanded to include patients with active brain metastases and three new drug therapies. Pharmaceutical company Boehringer Ingelheim has also joined the study and, later this year, will provide afatinib (Gilotrif®) to participants who enroll in a tissue-agnostic cohort of patients with an NRG1 gene fusion. That same month, the TAPUR Study also will add two new drugs from existing pharmaceutical company collaborators: abemaciclib (Verzenio®, Eli Lilly and Company) and talazoparib (Talzenna®, Pfizer).
Pages |
